Table 2.
Primary outcome and sensitivity analyses.
| Treated | Untreated | |
|---|---|---|
| Primary analysis: (adjusted for age, sex, WIMD, vaccination status, number of comorbidities) | ||
| Numbers included | 2040 | 4973 |
| No. of events (%) | 84 (4.1) | 544 (10.9) |
| Hazard ratio (95% CI) | 0.65 (0.51–0.82) | |
| Sensitivity analysis: unadjusted | ||
| Numbers included | 2040 | 4973 |
| No. of events (%) | 84 (4.1) | 544 (10.9) |
| Hazard ratio (95% CI) | 0.48 (0.38–0.61) | |
| Sensitivity analysis: (adjusted for age, sex, WIMD, vaccination status, clinical group) | ||
| Numbers included | 2040 | 4973 |
| No. of events (%) | 84 (4.1) | 544 (10.9) |
| Hazard ratio (95% CI) | 0.61 (0.48–0.78) | |
| Sensitivity analysis: (adjusted for age, sex, WIMD, vaccination status, weighted CCI score) | ||
| Numbers included | 2040 | 4973 |
| No. of events (%) | 84 (4.1) | 544 (10.9) |
| Hazard ratio (95% CI) | 0.67 (0.53–0.85) | |
| Sensitivity analysis: time-independent (adjusted for age, sex, WIMD, vaccination status, number of comorbidities) | ||
| Numbers included | 2072 | 4941 |
| No. of events (%) | 116 (5.6) | 512 (10.4) |
| Hazard ratio (95% CI) | 0.72 (0.58–0.88) | |
| Sensitivity analysis: logistic model (adjusted for age, sex, WIMD, vaccination status, number of comorbidities)a | ||
| Numbers included | 2072 | 4941 |
| No. of events (%) | 116 (5.6) | 512 (10.4) |
| Odds ratio (95% CI) | 0.70 (0.57–0.88) | |
a
The treated group included 32 individuals who received treatment after hospitalization.